Chengdu Zenitar Biomedical Technology Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2

Recruiting

Conditions: Cutaneous T-cell Lymphoma (CTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions: Drug: 11.2 mg/m2 Purinostat Mesylate
Drug: 15 mg/m2 Purinostat Mesylate

First Posted Date: 2024-07-03

Last Posted Date: 2025-04-08

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 50

Registration Number: NCT06485219

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions: Drug: Purinostat Mesylate 4 mg/m2
Drug: Purinostat Mesylate 6 mg/m2
Drug: Purinostat Mesylate 8.4 mg/m2

First Posted Date: 2024-07-03

Last Posted Date: 2025-04-02

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 144

Registration Number: NCT06484829

Locations: 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

Phase 2

Recruiting

Conditions: MF,PMF,PPV-MF,PET-MF

Interventions: Drug: Flonoltinib 50mg
Drug: Flonoltinib 100mg
Drug: Ruxolitinib

First Posted Date: 2024-06-13

Last Posted Date: 2025-04-10

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 75

Registration Number: NCT06457425

Locations: 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

ZL-82 Double-blind Clinical Trial

Phase 1

Recruiting

Conditions: Healthy Person

Interventions: Drug: ZL-82 placebo
Drug: ZL-82

First Posted Date: 2024-05-29

Last Posted Date: 2024-05-29

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 40

Registration Number: NCT06432738

Locations: 🇨🇳
Peking University Medical Shandong Hospital of Traditional Chinese Medicine, Zibo, Shandong, China

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: A0/B0 group Purinostat Mesylate 11.2mg/m2
Drug: A group Purinostat Mesylate 6mg/m2
Drug: B group Purinostat Mesylate 6 mg/m2
Drug: A group Purinostat Mesylate 8.4mg/m2
Drug: A0/B0 group Purinostat Mesylate 15mg/m2
Drug: B group Purinostat Mesylate 8.4 mg/m2
Drug: A group Purinostat Mesylate 11.2mg/m2
Drug: B group Purinostat Mesylate 11.2mg/m2
Drug: A group Purinostat Mesylate 15 mg/m2
Drug: B group Purinostat Mesylate 15mg/m2

First Posted Date: 2024-05-28

Last Posted Date: 2025-04-10

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 132

Registration Number: NCT06431243

Locations: 🇨🇳
West China hospital of Sichuan university, Chengdu, Sichuan, China
🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guanzhou, Guangzhou, China

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Phase 1

Recruiting

Conditions: Healthy Person

Interventions: Drug: flunotinib
Drug: flunotinib placebo

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 40

Registration Number: NCT06387966

Locations: 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China

Phase I Clinical Study of ZL-82 Tablets

Phase 1

Completed

Conditions: Rheumatoid Arthritis (RA)
Inflammatory Bowel Disease - IBD1

Interventions: Drug: ZL-82 12.5mg
Drug: zL-82 placebo 12.5mg
Drug: ZL-82 25mg
Drug: ZL-82 placebo 25mg
Drug: ZL-82 50mg
Drug: ZL-82 placebo 50mg
Drug: ZL-82 100mg
Drug: ZL-82 placebo 100mg
Drug: ZL-82 200mg
Drug: ZL-82 placebo 200mg
Drug: ZL-82 300mg
Drug: ZL-82 placebo 300mg
Drug: ZL-82 450mg
Drug: ZL-82 placebo 450mg
Drug: ZL-82 600mg
Drug: ZL-82 placebo 600mg

First Posted Date: 2023-09-26

Last Posted Date: 2025-04-03

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 69

Registration Number: NCT06055023

Locations: 🇨🇳
Affiliated Hospital of Guizhou Medical University, Guizhou, GuiYang, China

Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection

Not Applicable

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: SOC

First Posted Date: 2023-02-06

Last Posted Date: 2023-09-26

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 66

Registration Number: NCT05713279

Locations: 🇨🇳
Chengdu Zenitar Biomedical Technology Co., Ltd, Chengdu, Sichuan, China

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma，DLBCL

Interventions: Drug: PM 8.4 mg/m2
Drug: PM 11.2 mg/m2

First Posted Date: 2022-10-03

Last Posted Date: 2025-02-17

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 120

Registration Number: NCT05563844

Locations: 🇨🇳
Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma，DLBCL

Interventions: Drug: Prilinostat Mesylate 6.0mg/m2
Drug: Prilinostat Mesylate 8.4mg/m2
Drug: Prilinostat Mesylate 11.2mg/m2
Drug: Prilinostat Mesylate 15mg/m2
Drug: Prilinostat Mesylate 1.2mg/m2
Drug: Prilinostat Mesylate 2.4mg/m2
Drug: Prilinostat Mesylate 4.0mg/m2

First Posted Date: 2022-09-02

Last Posted Date: 2023-09-25

Lead Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Target Recruit Count: 29

Registration Number: NCT05526313

Locations: 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China

Home Terms & Conditions Privacy Policy